Pradaxa

Pradaxa

dabigatran

Manufacturer:

Boehringer Ingelheim

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Dabigatran etexilate
Indications/Uses
Prevention of VTE in patients who have undergone orthopaedic surgery for knee or hip replacement; stroke, systemic embolism & reduction of vascular mortality in patients w/ atrial fibrillation. Treatment of acute DVT &/or pulmonary embolism (PE). Prevention of recurrent DVT &/or PE & related death.
Dosage/Direction for Use
Adult VTE prevention following knee replacement surgery Initially one 110-mg cap w/in 1-4 hr of completed surgery; continue w/ 2 cap once daily thereafter for 10 days. VTE prevention following hip replacement surgery Initially one 110-mg cap w/in 1-4 hr of completed surgery; continue w/ 2 cap once daily thereafter for 28-35 days. Prevention of stroke, systemic embolism & reduction of vascular mortality Recommended dose: 150 mg bid. Therapy should be continued life-long. Treatment of acute DVT &/or PE & related death Recommended dose: 150 mg bid following treatment w/ parenteral anticoagulant for at least 5 days. Therapy should be continued up to 6 mth. Prevention of recurrent DVT &/or PE & related death Recommended dose: 150 mg bid. Therapy should be continued life-long. Catheter ablation for atrial fibrillation 150-mg cap bid does not need to be interrupted.
Administration
May be taken with or without food: Swallow whole, do not chew/crush.
Contraindications
Known hypersensitivity. Severe renal impairment (CrCl <30 mL/min). Haemorrhagic manifestations, bleeding diathesis, spontaneous or pharmacological impairment of haemostasis; organ lesions at risk of clinically significant bleeding including haemorrhagic stroke w/in the last 6 mth. Concomitant use w/ systemic ketoconazole. Prosthetic heart valve replacement.
Special Precautions
Hepatic impairment, renal insufficiency, increased hemorrhagic risk eg, recent biopsy or major trauma, bacterial endocarditis. Discontinue at least 24 hr before invasive or surgical procedure. Spinal/epidural anesth, lumbar puncture. Acute renal failure (discontinue). Patients w/ atrial fibrillation may stay on Pradaxa while being cardioverted. Pregnancy & lactation. Childn <18 yr.
Adverse Reactions
Anaemia, thrombocytopenia, pruritus, rash, urticaria, bronchospasm, angioedema, anaphylactic reaction, intracranial haemorrhage, haematoma, haemorrhage, epistaxis, haemoptysis, GI, skin & urogenital haemorrhage, abdominal pain, diarrhoea, dyspepsia, nausea, GI ulcer, oesophageal ulcer, gastrooesophagitis, GERD, vomiting, dysphagia, abnormal hepatic function, haemarthrosis, inj & catheter site haemorrhage, traumatic & incision site haemorrhage, wound haemorrhage & secretion, bloody discharge, post-procedural haematoma, haemorrhage & discharge, post-op anaemia, post-procedural & wound drainage.
Drug Interactions
Increased plasma conc w/ P-gp inhibitors eg, amiodarone, verapamil, quinidine, systemic ketoconazole, dronedarone, ticagrelor & clarithromycin. Reduced plasma conc w/ P-gp inducers eg, rifampicin.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AE07 - dabigatran etexilate ; Belongs to the class of direct thrombin inhibitors. Used in the treatment of thrombosis.
Presentation/Packing
Form
Pradaxa cap 110 mg
Packing/Price
3 × 10's
Form
Pradaxa cap 150 mg
Packing/Price
3 × 10's
Form
Pradaxa cap 75 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in